Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.

Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG.

J Clin Oncol. 2019 Sep 1;37(25):2246-2256. doi: 10.1200/JCO.19.00261. Epub 2019 Jul 8.

PMID:
31283407
2.

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.

Agraz-Doblas A, Bueno C, Bashford-Rogers R, Roy A, Schneider P, Bardini M, Ballerini P, Cazzaniga G, Moreno T, Revilla C, Gut M, Valsecchi MG, Roberts I, Pieters R, De Lorenzo P, Varela I, Menendez P, Stam RW.

Haematologica. 2019 Jun;104(6):1176-1188. doi: 10.3324/haematol.2018.206375. Epub 2019 Jan 24.

3.

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.

Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A, Pieters R, Baruchel A, Vora A, Leoni V, Stary J, Escherich G, Li CK, Cazzaniga G, Cavé H, Bradtke J, Conter V, Saha V, Schrappe M, Grazia Valsecchi M.

Lancet Haematol. 2018 Dec;5(12):e641-e652. doi: 10.1016/S2352-3026(18)30173-X.

PMID:
30501871
4.

Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.

Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso ÁM, Mora J, Locatelli F, Bertaina A, Padilla L, Rodríguez-Manzaneque JC, Bueno C, Menéndez P.

Leukemia. 2018 Oct;32(10):2306. doi: 10.1038/s41375-018-0236-4.

PMID:
30218009
5.

Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor.

Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M.

Haematologica. 2019 Jan;104(1):e13-e16. doi: 10.3324/haematol.2018.199422. Epub 2018 Sep 13. No abstract available.

6.

Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.

Parini R, De Lorenzo P, Dardis A, Burlina A, Cassio A, Cavarzere P, Concolino D, Della Casa R, Deodato F, Donati MA, Fiumara A, Gasperini S, Menni F, Pagliardini V, Sacchini M, Spada M, Taurisano R, Valsecchi MG, Di Rocco M, Bembi B.

Orphanet J Rare Dis. 2018 Feb 8;13(1):32. doi: 10.1186/s13023-018-0771-0.

7.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Driessen EMC, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R.

Leukemia. 2017 Dec;31(12):2854. doi: 10.1038/leu.2017.279.

PMID:
29210366
8.

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A.

Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.

9.

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.

Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso ÁM, Mora J, Locatelli F, Bertaina A, Padilla L, Rodríguez-Manzaneque JC, Bueno C, Menéndez P.

Leukemia. 2018 Mar;32(3):633-644. doi: 10.1038/leu.2017.294. Epub 2017 Sep 25. Erratum in: Leukemia. 2018 Oct;32(10):2306.

10.

Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.

Dander E, De Lorenzo P, Bottazzi B, Quarello P, Vinci P, Balduzzi A, Masciocchi F, Bonanomi S, Cappuzzello C, Prunotto G, Pavan F, Pasqualini F, Sironi M, Cuccovillo I, Leone R, Salvatori G, Parma M, Terruzzi E, Pagni F, Locatelli F, Mantovani A, Fagioli F, Biondi A, Garlanda C, Valsecchi MG, Rovelli A, D'Amico G.

Oncotarget. 2016 Dec 13;7(50):82123-82138. doi: 10.18632/oncotarget.13488.

11.

Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.

Trentin L, Bresolin S, Giarin E, Bardini M, Serafin V, Accordi B, Fais F, Tenca C, De Lorenzo P, Valsecchi MG, Cazzaniga G, Kronnie GT, Basso G.

Sci Rep. 2016 Oct 4;6:34449. doi: 10.1038/srep34449.

12.

Impact of Continuous vs Bolus Feeding on Splanchnic Perfusion in Very Low Birth Weight Infants: A Randomized Trial.

Bozzetti V, Paterlini G, De Lorenzo P, Gazzolo D, Valsecchi MG, Tagliabue PE.

J Pediatr. 2016 Sep;176:86-92.e2. doi: 10.1016/j.jpeds.2016.05.031. Epub 2016 Jun 20.

PMID:
27339251
13.

Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.

Parini R, Rigoldi M, Tedesco L, Boffi L, Brambilla A, Bertoletti S, Boncimino A, Del Longo A, De Lorenzo P, Gaini R, Gallone D, Gasperini S, Giussani C, Grimaldi M, Grioni D, Meregalli P, Messinesi G, Nichelli F, Romagnoli M, Russo P, Sganzerla E, Valsecchi G, Biondi A.

Mol Genet Metab Rep. 2015 Apr 22;3:65-74. doi: 10.1016/j.ymgmr.2015.03.011. eCollection 2015 Jun.

14.

Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia.

Driessen EM, Pinhanços SS, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Eur J Cancer. 2016 Apr;57:87-90. doi: 10.1016/j.ejca.2015.12.031. Epub 2016 Feb 19. No abstract available.

PMID:
26901613
15.

Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.

van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P, Valsecchi MG, Cazzaniga G, Biondi A, den Boer ML, Pieters R, Stam RW.

Haematologica. 2016 Mar;101(3):e95-8. doi: 10.3324/haematol.2014.122119. Epub 2015 Dec 17. No abstract available.

16.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R.

Leukemia. 2016 May;30(5):1184-7. doi: 10.1038/leu.2015.246. Epub 2015 Sep 15. No abstract available. Erratum in: Leukemia. 2017 Dec;31(12 ):2854.

PMID:
26369984
17.

Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia.

Lana T, de Lorenzo P, Bresolin S, Bronzini I, den Boer ML, Cavé H, Froňková E, Stanulla M, Zaliova M, Harrison CJ, de Groot H, Valsecchi MG, Biondi A, Basso G, Cazzaniga G, te Kronnie G.

Leukemia. 2015 Oct;29(10):2107-10. doi: 10.1038/leu.2015.78. Epub 2015 Mar 17. No abstract available.

PMID:
25778098
18.

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P.

Pediatr Blood Cancer. 2015 Mar;62(3):414-8. doi: 10.1002/pbc.25311. Epub 2014 Nov 18.

19.

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.

van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, Cavé H, Trka J, Saha V, Schrappe M, Pieters R, Biondi A, Valsecchi MG, Stanulla M, den Boer ML, Cazzaniga G.

Blood. 2014 Mar 13;123(11):1691-8. doi: 10.1182/blood-2013-06-509794. Epub 2013 Dec 23.

PMID:
24366361
20.

Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.

De Lorenzo P, Moorman AV, Pieters R, Dreyer ZE, Heerema NA, Carroll AJ, Hunger SP, Harvey R, Willman CL, Devidas M, Valsecchi MG, Harrison CJ.

Leukemia. 2014 Feb;28(2):428-30. doi: 10.1038/leu.2013.280. Epub 2013 Sep 27. No abstract available.

21.

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Haematologica. 2013 Jun;98(6):937-44. doi: 10.3324/haematol.2012.067983. Epub 2013 Feb 12.

22.

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.

Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi MG.

Lancet Oncol. 2012 Sep;13(9):936-45. doi: 10.1016/S1470-2045(12)70377-7. Epub 2012 Aug 14.

23.

Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.

Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, Felice M, Lausen B, Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG, Pieters R; Interfant-99 Study Group.

Blood. 2010 Oct 14;116(15):2644-50. doi: 10.1182/blood-2010-03-273532. Epub 2010 Jun 30.

PMID:
20592248
24.

Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment.

Jung R, Jacobs U, Krumbholz M, Langer T, Keller T, De Lorenzo P, Valsecchi MG, van der Velden VH, Moericke A, Stanulla M, Teigler-Schlegel A, Panzer-Gruemayer ER, van Dongen JJ, Schrappe M, den Boer ML, Pieters R, Rascher W, Metzler M.

Leukemia. 2010 Apr;24(4):903-7. doi: 10.1038/leu.2010.14. Epub 2010 Feb 18. No abstract available.

PMID:
20164851
25.

Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants.

Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX, de Lorenzo P, Valsecchi MG, Pieters R.

Blood. 2010 Apr 8;115(14):2835-44. doi: 10.1182/blood-2009-07-233049. Epub 2009 Dec 23.

PMID:
20032505
26.

Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.

Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R.

Blood. 2010 Feb 4;115(5):1018-25. doi: 10.1182/blood-2009-02-205963. Epub 2009 Dec 4.

PMID:
19965632
27.

Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.

Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW.

Blood. 2009 Dec 24;114(27):5490-8. doi: 10.1182/blood-2009-06-227660. Epub 2009 Oct 23.

PMID:
19855078
28.

Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.

Hempel G, Relling MV, de Rossi G, Stary J, De Lorenzo P, Valsecchi MG, Barisone E, Boos J, Pieters R.

Pediatr Blood Cancer. 2010 Mar;54(3):355-60. doi: 10.1002/pbc.22266.

PMID:
19731319
29.

Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.

van der Linden MH, Valsecchi MG, De Lorenzo P, Möricke A, Janka G, Leblanc TM, Felice M, Biondi A, Campbell M, Hann I, Rubnitz JE, Stary J, Szczepanski T, Vora A, Ferster A, Hovi L, Silverman LB, Pieters R.

Blood. 2009 Oct 29;114(18):3764-8. doi: 10.1182/blood-2009-02-204214. Epub 2009 Aug 5.

PMID:
19657114
30.

Evaluation of alternative prognostic stratifications by prediction accuracy measures on individual survival with application to childhood leukaemia.

De Lorenzo P, Antolini L, Valsecchi MG.

Eur J Cancer. 2009 May;45(8):1432-7. doi: 10.1016/j.ejca.2009.01.011. Epub 2009 Feb 14.

PMID:
19223176
31.

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ; Interfant-99 Study Group.

Leukemia. 2009 Jun;23(6):1073-9. doi: 10.1038/leu.2009.17. Epub 2009 Feb 12.

PMID:
19212338
32.

Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia.

Lönnerholm G, Valsecchi MG, De Lorenzo P, Schrappe M, Hovi L, Campbell M, Mann G, Janka-Schaub G, Li CK, Stary J, Hann I, Pieters R; Interfant-99 study group.

Pediatr Blood Cancer. 2009 May;52(5):596-601. doi: 10.1002/pbc.21925.

PMID:
19132729
33.

Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index.

Parini R, Rigoldi M, Santus F, Furlan F, De Lorenzo P, Valsecchi G, Concolino D, Strisciuglio P, Feriozzi S, Di Vito R, Ravaglia R, Ricci R, Morrone A.

Clin Genet. 2008 Sep;74(3):260-6. doi: 10.1111/j.1399-0004.2008.01012.x. Epub 2008 Apr 24.

PMID:
18445046
34.

Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time.

Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, Klingebiel T, Stary J, Felice MS, Magyarosy E, Schrappe M, Dini G, Gadner H, Valsecchi MG.

Haematologica. 2008 Jun;93(6):925-9. doi: 10.3324/haematol.12291. Epub 2008 Apr 15.

35.

Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.

Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R.

Blood. 2007 Oct 1;110(7):2774-5. No abstract available.

PMID:
17881645
36.

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG.

Lancet. 2007 Jul 21;370(9583):240-250. doi: 10.1016/S0140-6736(07)61126-X.

PMID:
17658395
37.

Web-based international studies in limited populations of pediatric leukemia.

Valsecchi MG, Silvestri D, Covezzoli A, De Lorenzo P.

Pediatr Blood Cancer. 2008 Feb;50(2):270-3.

PMID:
17486643
38.

Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.

Biondi A, Rizzari C, Valsecchi MG, De Lorenzo P, Aricò M, Basso G, Locatelli F, Lo Nigro L, De Rossi G, Masera G.

Haematologica. 2006 Apr;91(4):534-7. Epub 2006 Mar 15.

39.

Analysis of interval-censored longitudinal data with application to onco-haematology.

De Lorenzo P, Henderson R, Valsecchi MG.

Stat Med. 2005 Dec 30;24(24):3945-57.

PMID:
16320268
40.

Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.

Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H, Schrappe M.

Lancet. 2005 Aug 20-26;366(9486):635-42.

PMID:
16112299
41.

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R.

Blood. 2005 Oct 1;106(7):2484-90. Epub 2005 Jun 14.

PMID:
15956279
42.

Clinical epidemiology of childhood cancer in Central America and Caribbean countries.

Valsecchi MG, Tognoni G, Bonilla M, Moreno N, Baez F, Pacheco C, Hernandez AP, Antillon-Klussmann F, Machin S, Cabanas R, Navarrete M, Nieves R, De Lorenzo P, Masera G; Monza's International School of Paediatric Hematology-Oncology.

Ann Oncol. 2004 Apr;15(4):680-5.

PMID:
15033679
43.

Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission.

Uderzo C, Balduzzi A, De Lorenzo P, Valsecchi MG, Gadner H, Klingebiel T, Zimmermann M, Schrappe M; EBMT Pediatric Working Group; I-BFM SG.

Bone Marrow Transplant. 2001 Aug;28 Suppl 1:S22-4. No abstract available.

44.

Autologous hematopoietic stem cell transplantation (AHSCT) as consolidation therapy for childhood acute myelogenous leukemia in 1st complete remission.

Biagi E, Rovelli A, De Lorenzo P, Uderzo C.

Pediatr Hematol Oncol. 2001 Jul-Aug;18(5):359-62. No abstract available.

PMID:
11452409
45.

Predictors of failure of transoesophageal cardioversion of common atrial flutter.

Vincenti A, Ciro A, De Ceglia S, Valsecchi MG, De Lorenzo P.

Europace. 2001 Jan;3(1):10-5.

PMID:
11271944
46.

TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission.

Biagi E, Rovelli A, Balduzzi A, De Lorenzo P, Tagliabue A, Uderzo C.

Bone Marrow Transplant. 2000 Dec;26(11):1260-2. No abstract available.

47.

Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.

Uderzo C, Fumagalli M, De Lorenzo P, Busca A, Vassallo E, Bonanomi S, Lanino E, Dini G, Varotto S, Messina C, Miniero R, Valsecchi MG, Balduzzi A.

Bone Marrow Transplant. 2000 Nov;26(9):1005-9. Review.

48.

Early and late deaths after elective end of therapies for childhood cancer in Italy.

Haupt R, Valsecchi MG, Silvestri D, De Lorenzo P, Napoli S, Masera G, Terracini B, Jankovic M.

Int J Cancer. 2000 May 1;86(3):393-8.

Supplemental Content

Loading ...
Support Center